New AAM CEO: Traditional Lobbying On Lowering Health Care Costs Can Mix With COVID-19 Talks
Executive Summary
Dan Leonard is working on post-pandemic generic drug issues, using coronavirus as a way to get in front of lawmakers.
You may also be interested in...
AAM Unveils ‘Long Overdue’ Membership Roles
The US Association for Accessible Medicines has for the first time appointed two member-focused roles within its organization, as long-serving policy executive Christine Simmon was also handed a promotion.
Generic Industry’s Future May Include A Role In The Gene Therapy Space
Trade association’s CEO says a new strategic planning initiative will consider among other things how gene therapy could fit into the generic industry business model.
ANDA Submissions Drop To Start FY2021
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.